Simulations Plus Announces Launch of ADMET Predictor Version 12
In a significant development for the field of cheminformatics, Simulations Plus has revealed the latest update to their flagship software, ADMET Predictor, now in its 12th iteration. This new version introduces cutting-edge enhancements designed to significantly improve the predictive capabilities and efficiencies within drug discovery and development research.
At the heart of ADMET Predictor Version 12 are the newly boosted Artificial Neural Network (ANN) Regression Models, a powerful tool for researchers that simulate and predict how new chemical compounds might behave in the body, including their effects, metabolism, and potential toxicity. Coupled with the introduction of 37 novel descriptors in the ADMET Modeler, this update is poised to revolutionize the software’s utility and accuracy.
Dr. David Miller, Vice President of Cheminformatics at Simulations Plus, shared his insights into the profound impact of these updates: “ADMET Predictor 12 features substantial advancements in the critical components required to build high-quality machine learning models. This upgraded version integrates new premium data, novel descriptors, and robust algorithms that will increase our customers’ ability to predict with confidence.”
These improvements underscore the commitment of Simulations Plus to provide cutting-edge tools for the scientific community, aiming to streamline the complex processes of drug discovery and development. By incorporating novel data and expanding the software’s architectural complexity, the new version of ADMET Predictor delivers an unparalleled predictive performance that researchers can rely on.
Additionally, based on valuable customer feedback, the software has been enhanced not just in terms of its core predictive functionalities but also in its integration and automation capabilities within existing workflows. Dr. Eric Jamois, Director of Key Accounts and Strategic Alliances at Simulations Plus, elaborated on this point: “The advances embedded in AP12 deliver downstream benefits in High Throughput Pharmacokinetics (HTPK), Artificial Intelligence-Driven Drug Discovery (AIDD), and now, High Throughput Drug-Induced Liver Injury (HT-DILI).”
This thoughtful integration seeks to offer a seamless experience for users, complementing their existing systems and processes and enabling a more holistic, efficient approach to drug discovery research. Through these enhancements, Simulations Plus not only responds to the direct needs and requests of its user base but also leads the way in innovative drug discovery technology.
The enthusiasm from Simulations Plus regarding the launch of ADMET Predictor Version 12 is palpable, reflecting a broader trend within the scientific community towards leveraging technology and artificial intelligence to enhance research outcomes. With the ongoing enhancements and innovations provided by updates like these, researchers are better equipped than ever to navigate the intricate processes of drug discovery, mitigating risks and maximizing efficacy in developing new therapeutics.
In conclusion, the release of ADMET Predictor Version 12 marks another step forward in the quest for more predictive, efficient, and integrated tools in drug discovery and development. Simulations Plus continues to solidify its position as a leader in the field, offering advanced solutions that empower researchers to achieve their goals with greater precision and confidence.
